Adragos Pharma Strengthens Sterile Manufacturing Capabilities with Baccinex Acquisition

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - stock.adobe.com

German contract development and manufacturing organization (CDMO), Adragos Pharma, has announced its acquisition of Swiss aseptic fill/finish manufacturing company, Baccinex, in a Nov. 25, 2024 press release (1). Through the acquisition, Adragos Pharma will enhance its sterile manufacturing capabilities and expand its global network.

Baccinex has more than 20 years of experience in aseptic fill/finish services for liquid and lyophilized vials and is based in Courroux, Jura, in Switzerland. The company’s Jura facility is both European Union (EU)-good manufacturing practice (GMP) and US FDA-certified and specializes in clinical trial supplies and small-to-medium scale commercial production.

Under the acquisition agreement, Dr. Ursula Bausch, who founded Baccinex, will continue her position as CEO and she will also remain a shareholder in the company. “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide,” Bausch said in the press release (1).

Additionally, the acquisition of Baccinex aligns with Adragos Pharma’s global expansion strategy. “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing,” added Dr. Andreas Raabe, founder and CEO of Adragos Pharma, in the press release (1).

Adragos Pharma has been making strides to further its global footprint with various acquisitions and, in addition to the most recent Swiss addition, has manufacturing sites located in Germany, France, Greece, Norway, and Japan.

On Nov. 7, 2024, the company announced the launch of a cutting-edge ampoule filling line at its Livron facility in France, enhancing its production capacity to over 160 million ampoules per year (2). “We recognized not only a regulatory demand in Annex 1 but also an urgent need for greater capacity, particularly for larger-volume ampoules. That’s why we installed this fourth line, allowing us to offer a capacity of over 160 million ampoules, including options up to 20 mL, tailored to serve our clients’ evolving requirements,” explained Marco Gorgas, CCO of Adragos Pharma in a press release (2).

In April 2024, Adragos Pharma also highlighted its actions to reinvest in the solid dosage market through their plans to enhance the manufacturing capacity of its Kawagoe plant in Japan to meet the anticipated demand of 2 billion tablets in the future (3). “Our business has progressed seamlessly, surpassing our initial goals. Moving into the second year and beyond, we will further enhance the manufacturing capacity of the Kawagoe plant, primarily focusing on solid formulations, to meet (growing) demands,” stated Keizo Yanagisawa, president and representative director of Adragos Pharma, in a press release (3).

References

1. Adragos Pharma. Adragos Pharma Acquires Baccinex—A Leading Swiss Sterile Fill-Finish Expert. Press Release, Nov. 25, 2024.Swiss Sterile Fill-Finish Expert. Press Release, Nov. 25, 2024.
2. Adragos Pharma. Project Future: We Launched Our New Production Line in Our Livron Facility! Press Release, Nov. 7, 2024.
3. Adragos Pharma. Our Strategic Expansion in Japan: Reinforcing Production to 2 Billion Tablets and Aiming to be the “Most Trusted CDMO”. Press Release, April 8, 2024.